A bispecific T‑cell engager (BiTE) antibody construct that binds CD19 on B cells and CD3 on T cells, redirecting cytotoxic T cells to kill CD19-positive leukemia cells.
Blinatumomab is a bispecific anti-CD19×CD3 antibody that bridges CD19-positive B cells and CD3-positive T cells, activating TCR/CD3 signaling to redirect cytotoxic T cells to kill CD19-expressing leukemia cells via immune synapse formation and perforin/granzyme-mediated lysis.
YES
DIRECT
Blinatumomab links CD19 on target cells to CD3 on T cells, forming an immune synapse and activating T cells to kill CD19+ cells via perforin/granzyme-mediated cytotoxicity.
A bispecific T‑cell engager (BiTE) antibody construct that binds CD19 on B cells and CD3 on T cells, redirecting cytotoxic T cells to kill CD19-positive leukemia cells.
Blinatumomab is a bispecific anti-CD19×CD3 antibody that bridges CD19-positive B cells and CD3-positive T cells, activating TCR/CD3 signaling to redirect cytotoxic T cells to kill CD19-expressing leukemia cells via immune synapse formation and perforin/granzyme-mediated lysis.
NO
INDIRECT
Blinatumomab binds CD3 on T cells to recruit them to CD19+ cells, leading to perforin/granzyme-mediated lysis of the CD19+ targets; CD3+ T cells are not killed.
Investigational immunotherapy drug administered as a short-term intravenous infusion; specific mechanism, target, and modality not disclosed. Studied as monotherapy in a Phase 1 first-in-human dose-escalation and expansion trial for adults with advanced solid tumors.
AMG 305 is a T‑cell–engaging bispecific antibody that binds CD3 on cytotoxic T cells and simultaneously recognizes the tumor-associated antigens cadherin‑3 (CDH3) and mesothelin (MSLN) on tumor cells. By crosslinking T cells to tumor cells co‑expressing CDH3 and MSLN, it activates T‑cell cytotoxicity and promotes selective lysis of dual‑positive tumor cells, improving specificity and limiting activity against normal tissues expressing only one antigen.
YES
DIRECT
AMG 305 is a T‑cell–engaging bispecific that links CD3 on T cells to CDH3 and MSLN on tumor cells, activating T cells to kill dual‑positive cells via perforin/granzyme‑mediated cytolysis; CDH3-only cells are largely spared.
Investigational immunotherapy drug administered as a short-term intravenous infusion; specific mechanism, target, and modality not disclosed. Studied as monotherapy in a Phase 1 first-in-human dose-escalation and expansion trial for adults with advanced solid tumors.
AMG 305 is a T‑cell–engaging bispecific antibody that binds CD3 on cytotoxic T cells and simultaneously recognizes the tumor-associated antigens cadherin‑3 (CDH3) and mesothelin (MSLN) on tumor cells. By crosslinking T cells to tumor cells co‑expressing CDH3 and MSLN, it activates T‑cell cytotoxicity and promotes selective lysis of dual‑positive tumor cells, improving specificity and limiting activity against normal tissues expressing only one antigen.
YES
DIRECT
AMG 305 crosslinks CD3 on T cells to mesothelin and CDH3 on tumor cells, activating T-cell cytotoxicity (perforin/granzyme) to lyse cells co-expressing mesothelin and CDH3.
Investigational immunotherapy drug administered as a short-term intravenous infusion; specific mechanism, target, and modality not disclosed. Studied as monotherapy in a Phase 1 first-in-human dose-escalation and expansion trial for adults with advanced solid tumors.
AMG 305 is a T‑cell–engaging bispecific antibody that binds CD3 on cytotoxic T cells and simultaneously recognizes the tumor-associated antigens cadherin‑3 (CDH3) and mesothelin (MSLN) on tumor cells. By crosslinking T cells to tumor cells co‑expressing CDH3 and MSLN, it activates T‑cell cytotoxicity and promotes selective lysis of dual‑positive tumor cells, improving specificity and limiting activity against normal tissues expressing only one antigen.
NO
INDIRECT
CD3 is on T cells; AMG 305 binds CD3 to recruit and activate T cells, which then kill CDH3/MSLN dual-positive tumor cells via perforin/granzyme-mediated cytolysis. CD3+ cells themselves are not killed.